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Objectives This study investigated the impact on recurrences of 2 different substrate approaches for the treatment of
these arrhythmias.
Background Catheter ablation of electrical storms (ES) for ventricular arrhythmias (VAs) has shown moderate long-term
efficacy in patients with ischemic cardiomyopathy.
Methods Ninety-two consecutive patients (81% male, age 62  13 years) with ischemic cardiomyopathy and ES under-
went catheter ablation. Patients were treated either by confining the radiofrequency lesions to the endocardial
surface with limited substrate ablation (Group 1, n  49) or underwent endocardial and epicardial ablation of
abnormal potentials within the scar (homogenization of the scar, Group 2, n  43). Epicardial access was ob-
tained in all Group 2 patients, whereas epicardial ablation was performed in 33% (14) of these patients.
Results Mean ejection fraction was 27  5. During a mean follow-up of 25  10 months, the VAs recurrence rate of any
ventricular tachycardia (VTs) was 47% (23 of 49 patients) in Group 1 and 19% (8 of 43 patients) in Group 2
(log-rank p  0.006). One patient in Group 1 and 1 patient in Group 2 died at follow-up for noncardiac reasons.
Conclusions Our study demonstrates that ablation using endo-epicardial homogenization of the scar significantly increases
freedom from VAs in ischemic cardiomyopathy patients. (J Am Coll Cardiol 2012;60:132–41) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.044Patients with ischemic heart disease and reduced left ven-
tricular systolic function are at high risk for developing
sustained ventricular arrhythmias (VAs) and sudden cardiac
death (1). Ventricular monomorphic tachycardia is the most
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July 10, 2012:132–41 Endo-Epicardial Homogenization of the Scardefibrillators (ICDs) are mandatory in these patients and
have shown efficacy in reducing mortality (1). However,
several studies suggest that ICD shocks may reduce quality
of life and increase mortality (1, 2). In order to reduce ICD
shocks and improve quality of life, antiarrhythmic drugs
(AADs) can be administered in these patients, although with
several side effects and unsatisfactory results (1). The presence
f the ICD allowed us to define a condition of ventricular
nstability characterized by the presence of multiple VAs in a
rief period of time (3). Electrical storm (ES) is defined as the
ccurrence of 3 episodes of sustained VA requiring ICD
ntervention in the 24 h (3). In patients with secondary
rophylaxis ICD implantation, the reported incidence of ES
anges from 10% to 40%, whereas in the primary prevention
roup, the range is between 3% and 5% (3–9). The clinical
anagement of these patients involves multiple treatment
odalities, including medical treatment with AADs and
ntiadrenergic drugs, catheter ablation, and sophisticated
ystems for hemodynamic support (4). The reported mor-
ality at follow-up is high, and the ES has been reported as
predictor for cardiovascular death (6,10–12).
In order to improve quality of life and reduce the VA
pisodes, catheter ablation has been considered as a valid
reatment option in addition to medical treatment in this
etting, although only a moderate long-term efficacy at
ollow-up has been reported (13,14). These procedures are
ery challenging due to technical aspects, hemodynamic
ntolerance, and the complex arrhythmia substrates (4,14).
The complex anatomy of the endocardial scar and mul-
iple potential reentrant pathways as well as initiators
epresents the main limitations of VAs ablation (15–19).
his is why a limited substrate ablation might abolish
ircuits relevant to the arrhythmia burden at the time of the
rocedure (4,14). However, whether more extensive abla-
ion targeting every area showing diseased recordings could
e more successful at long term is unknown.
We sought to investigate the impact on recurrences of 2
ifferent substrate approaches for the treatment of these
rrhythmias.
ethods
atient population. Ninety-two consecutive patients with
schemic cardiomyopathy and ES (defined as 3 ICD
nterventions in 24 h) undergoing ablation at 5 different
nstitutions were enrolled in this prospective study. All
atients had an ICD before the ablation and suffered from
S despite AADs such as beta-blockers, dofetilide, amio-
arone, mexiletine, sotalol, and ICD therapies. Exclusion
riteria included severe renal insufficiency, mobile left ven-
ricle thrombus, unstable angina, severe aortic stenosis and
nd-stage heart failure (New York Heart Association func-
ional class IV with a limited survival expectation at 12
onths), previous coronary artery bypass graft, age 18ears, and prior failed VA ablations. tFrom March 2007 to August
008, consecutive patients were
reated only by confining the ra-
iofrequency lesions to the endo-
ardial surface with limited sub-
trate ablation (Group 1, n 49,
onventional ischemic ventricu-
ar tachycardia [VT] ablation),
hereas from September 2008 to
ecember 2009, consecutive pa-
ients were treated by endocardial
nd epicardial ablation of all poten-
ials within and around the scar (ho-
ogenization procedure, Group 2,
 43).
The study was approved by the
nstitutional Review Board at each
articipating center, and all patients
igned an informed written consent.
lectrophysiology study and catheter ablation. All pa-
ients underwent the procedure in the fasting state under
onscious sedation. Arterial blood pressure and O2 satura-
ion monitoring was obtained in all patients. Antiarrhyth-
ic medications were stopped several days before the
rocedure when applicable. Standard transvenous multipo-
ar catheters were placed into the cardiac chambers appro-
riate for the arrhythmia being studied.
In all patients in Group 2 before ablation and systemic
eparinization, and only when required in patients in Group
(after systemic heparinization reversal, see later text),
ubxiphoid epicardial access was obtained by fluoroscopic
uidance as previously described (20).
Before epicardial ablation, coronary angiography was
erformed at operator’s discretion to avoid coronary artery
amage. Epicardial phrenic nerve capture was identified by
liciting diaphragmatic stimulation with bipolar pacing at
0 mA with a pulse width of 10 ms from the distal pole of
he ablation catheter.
Endocardial mapping was performed in all patients,
hereas epicardial mapping was performed once the epicar-
ial space was accessed in all Group 2 patients. Mapping in
he coronary sinus was performed via the femoral vein
pproach. Left ventricular mapping was performed via the
etrograde aortic or transseptal approach.
Tridimensional electroanatomical maps (CARTO, Bio-
ense Webster, Diamond Bar, California), including acti-
ation and voltage map, were obtained in sinus rhythm
nd/or during hemodynamically stable VT with the 3.5-mm
pen irrigated tip catheter (Biosense Webster) in all patients
ith the fill threshold setting at 15 mm. Intracardiac signals
ere filtered at 30 to 400 Hz.
All patients underwent bipolar substrate mapping with
tandard scar settings defined as normal tissue greater than
.5 mV and severe scar0.5 mV. Dense scar was defined as
reas with amplitudes less than the baseline noise level of
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
CI  confidence interval
ECG  electrocardiogram
ES  electrical storm
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
VA  ventricular arrhythmia
VF  ventricular fibrillation
VT  ventricular
tachycardiahe recording system, and these areas were color coded as
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Endo-Epicardial Homogenization of the Scar July 10, 2012:132–41gray. Maps included more points around areas of scar,
particularly focusing on the scar border and electrograms
within the scar. Normal tissue was less densely mapped.
Areas of fractionated or late potentials were tagged with
dots colored to denote the electrograms type. These nota-
tions were done irrespective of the voltage obtained. Maps
were considered complete when the entire chamber of
interest was completely mapped and all scar borders were
learly defined. Intracardiac echocardiography was used to
ssist in defining mechanical structures, monitoring for poten-
ial complications, and assisting in trans-septal puncture.
In both groups, ablation was performed using an open
rrigated 3.5-mm catheter. In Group 1, ablation was per-
ormed at putative VT(s) exit site(s) for at least 1 min until
ocal electrogram abatement and/or loss of capture (high-
utput pacing up to 20 mA with a pulse duration of 10 ms)
ere achieved, with up to 50 W and a temperature limit of
0°. In Group 2, ablation was performed at each single site
howing abnormal electrograms for at least 30 s with up to
0 W and a temperature limit of 40° if the abnormal
otential disappeared quickly, but it was prolonged in case
f persistent recordings.
The radiofrequency parameters in the epicardium were
he same as in the endocardium. Systemic anticoagulation
as achieved by intravenous heparin with a minimum
ctivation clotting time of 300 s.
No specific anticoagulant therapy was instituted after
blation, although all patients were under treatment with
ither aspirin or clopidogrel (or both).
blation in Group 1. STANDARD VT ABLATION. Conven-
tional mapping techniques including pace mapping, activa-
tion mapping, and entrainment mapping were used to
define the mechanism of the arrhythmias and identify
potential sites for ablation. After substrate mapping was
completed, an electrophysiology study was performed with the
intention of inducing the clinical VT. The clinical tachycardia
was defined as matching the clinical cycle lengths and mor-
phology seen on the 12-lead electrocardiograms (ECGs) and
on the ICD interrogation when available.
Programmed ventricular stimulation was performed in-
cluding 3 extra stimuli from 2 different right ventricle sites,
burst pacing, and using medications such as intravenous
isoproterenol (up to 5 g/min). If the clinical tachycardia
as not inducible, pacing was performed within the area of
car. Once a VT was induced, standard activation/
ntrainment mapping were performed (if tolerated), and
blation was performed until the VT was no longer induc-
ble. After that, the stimulation protocol was repeated and
ontinued until refractoriness of the 3 extrastimuli or
nduction of ventricular fibrillation (VF) from 2 different
ites. Earliest activation was defined in reference to a surface
CG lead. If possible, complete activation maps of the
hamber of interest were performed. Furthermore, entrain-
ent mapping and pace mapping techniques were used to
onfirm appropriate ablation sites. Ablation was performed
t the optimal ablation sites based on the preceding criteria, treferentially in tachycardia to observe cycle length slowing
nd termination. The target for ablation of tolerated VTs
as identified by mid-diastolic electrograms and confirmed
y entrainment with concealed fusion. Potential channels
ithin the scar were identified by substrate mapping and
argeted only when confirmed to be part of the VT circuits by
ntrainment mapping. Short linear ablation lesions were placed
cross the VT isthmus to terminate any inducible VTs (14).
In patients who did not tolerate the ventricular tachycar-
ia, we adopted a stepwise approach consisting of the
ollowing: 1) programmed ventricular stimulation to induce
he clinical VT; 2) localization of the myocardial infarct
hrough 3-dimensional electroanatomical voltage mapping;
nd 3) selective targeting of the potentially “arrhythmogenic
reas” of the infarct with catheter ablation based on the
orphology of the clinical VT and the induced VTs. The
2-lead ECGs were obtained for all inducible arrhythmias.
herefore, a high-density 3-dimensional substrate map of
he left ventricle was obtained. Once the substrate map was
onstructed, we used a standardized approach to identify the
imited regions of the infarct that represented the arrhyth-
ogenic tissue to selectively target for catheter ablation.
he most widely adopted approach was pace mapping
uring sinus rhythm or ventricular pacing (in case of
acemaker-dependent rhythm) predominantly along the
nfarct border zone, as defined according to voltage criteria
n 3-dimensional map (i.e., bipolar voltages between 0.5
nd 1.5 mV). Multiple pace-mapping points (at least 20
ollected approximately 5 mm apart, ranging from 20 to 40)
ere acquired in each patient, moving the catheter along the
car. The pace-mapping points showing with the best match
ith the clinical/induced VT morphology were tagged in a
ifferent color. The site with a paced 12-lead QRS mor-
hology matching 10/12 ECG leads of an inducible
onomorphic VT was presumed to be the exit site of that
T and was targeted for ablation with short linear lesions.
he latter were performed starting from the scar border
one toward the center of the substrate (dense scar) and
omposed of multiple and contiguous sequential lesions.
he lesions were empirically extended to cover all the
resumed VT(s) exit site(s), according to previously col-
ected pace mapping data.
Activation maps were also attempted in patients who
ould only tolerate short periods of VT and was limited to
he area of abnormal electrograms. Every effort was exer-
ised to also adopt entrainment mapping if the monomor-
hic VT was at least transiently hemodynamically stable.
In patients with persistent inducibility after endocardial
blation, epicardial access, mapping, and ablation were per-
ormed. In this subset of patients, systemic heparinization was
eversed with protamine before obtaining the epicardial access.
Regarding the mapping procedure, once scar was defined,
he isthmus of slow conduction was identified by activation
nd entrainment mapping when applicable. In the case of
ontolerated VTs, ablation was performed guided by elec-
roanatomical mapping and pace mapping, limiting the
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July 10, 2012:132–41 Endo-Epicardial Homogenization of the Scarapplications to the site of origin of the VTs (Fig. 1).
Cardiopulmonary support was used in 4 patients with the
left ventricle assist device (Impella Recover LP 2.5,
ABIOMED, Inc., Danvers, Massachusetts) due to pro-
longed hypotension after repeated VT inductions and ex-
ternal cardioversions. As previously mentioned, in this
group, the mean duration of each ablation lesion was longer
compared with the homogenization group and lasted for at
least 1 min. After ablation, programmed electrical stimula-
tion with and without isoproterenol was repeated as previ-
ously described. Any reliably inducible VTs were targeted
for further ablation, and the entire stimulation protocol was
repeated subsequently until the endpoint was achieved.
Ablation in Group 2. HOMOGENIZATION OF THE SCAR.
Both voltage and activation mapping procedures were the
same as previously described except for careful identification
of fractionated or delayed electrograms. The purpose of
activation mapping was to confirm that the VT was asso-
ciated with the identified scars. In this group, based on the
Figure 1 VT Ablation in a Patient From Group 1
(A) The 12-lead electrocardiogram (ECG) of the ventricular tachycardia (VT). (B) In
isthmus. (C) Interruption of the VT during ablation in the isthmus. (B,C) From top
voltage map of the left ventricle (LV) endocardium. Regions in red represent scar (
voltage 1.5 mV). Other colored regions represent abnormal myocardial regions (b
Red dots display ablation point across the VT isthmus. Note: the number of ablat
dots were acquired during the same radiofrequency application.substrate map, ablation was empirically extended through-
out the entire scar (homogenization of the scar) endocardi-
ally. In addition to voltage criteria, “abnormal” electrograms
both in the endocardium and the epicardium including
delayed and fragmented recordings were targeted. Epicar-
dially, we targeted the area presenting abnormal recordings
when it contained at least 3 abnormal electrograms. After
endocardial ablation, the epicardial scar was remapped, and
if areas of abnormal recordings were still present, then
ablation was performed. In this regard, “normal” electro-
grams were defined as electrograms with 3 or fewer sharp and
discrete deflections from baseline, amplitude 1.5 mV, dura-
tion 70 ms (and/or ratio amplitude/duration 0.046) (21).
ny electrograms not fitting the latter definition were
ategorized as “abnormal” and targeted for ablation. In the
resence of dense scar at the noise level, no ablation was
elivered, and epicardial homogenization was performed
nly in patients showing large areas of epicardial delayed or
ractionated potentials.
of the VT with programmed ventricular stimulation from within the critical
tom, 12-lead ECG and ablation catheter recording (distal to proximal). (D) Bipolar
r voltage 0.5 mV), and purple regions represent normal myocardium (bipolar
voltage between 0.5 and 1.5 mV). The scar is located in the inferobasal LV.
s might overestimate the actual number of ablation applications, because someduction
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Endo-Epicardial Homogenization of the Scar July 10, 2012:132–41The goal of this ablation strategy was covering the entire
scar with ablation lesions targeting abnormal electrograms.
In the first 10 patients, pacing was performed at high output
(up to 20 mA with a pulse duration of 10 ms) from within
the ablated area, but capture was not seen and not tested in
later patients. Ablation at the border zone or within the
dense scar had the same procedural endpoint (i.e., abolition
of all abnormal potentials) (Figs. 2 and 3). At the end of the
blation, programmed stimulation with and without isopro-
erenol was performed in all cases to test the inducibility of
ny VAs following extensive substrate ablation.
rocedural endpoint. Although with a different ablation
echnique, in both groups after ablation the acute procedural
ndpoint was the noninducibility of any monomorphic VTs
efore and after the administration of isoproterenol (up to
g/min). Induction of nonclinical very fast VT (cycle
ength 200 ms), or VF, ventricular flutter, or fast poly-
orphic VT were not considered as a procedural endpoint
nd were not taken into account.
ollow-up. In all patients, screening for pericardial effu-
ion was routinely done at the end of the procedure by
ntracardiac echocardiography and fluoroscopy. In case of
atients’ symptoms or low blood pressure after the proce-
Figure 2 Bipolar Voltage Map of the LV Endocardium in a Patie
Regions in red represent scar (bipolar voltage 0.5 mV), and purple regions repre
abnormal myocardial regions (bipolar voltage between 0.5 and 1.5 mV). The scar
storm despite amiodarone 400 twice per day  mexiletine 150 three times per da
(EGMs) of representative endocardial mapping sites are shown with white arrows.
mal (MAP 3-MAP 4) and distal (MAP 1-MAP 2) ablation catheter are shown. Note:
tions, because some dots were acquired during the same radiofrequency applicatiures, transthoracic echocardiography was performed before
ischarge.
All patients were followed up with remote monitoring as
ell as implantable device interrogations and office visits
very 3 months thereafter to assess recurrences.
Arrhythmia recurrence was defined as arrhythmias receiv-
ng device-based treatments (anti-tachycardia pacing [ATP]
r shock). After ablation, the previously ineffective AADs
ere given and discontinued 3 months later. After the
rocedures, all ICDs were programmed to detect VTs
lower than the clinical VTs. No differences in the program-
ing modality in between groups were present.
tatistical analysis. Continuous data are described as
ean  SD and as numbers and percentages if categorical.
tudent t test, chi-square test, and Fisher exact test were
sed to compare differences across groups. Multivariable
ox regression analysis was used for identifying significant
redictors of VA recurrence while controlling for clinically
elevant covariates. All potential confounders were entered
nto the model based on significant univariable association
r prior knowledge or expected clinical relevance, regardless
f their statistical significance. The proportional hazard
om Group 2
ormal myocardium (bipolar voltage 1.5 mV). Other colored regions represent
ted in the inferior left ventricle (LV). This patient had ventricular tachycardia
entire scar has been targeted with extensive ablation (red dots). Electrograms
ch EGM recording, electrocardiogram leads I, V1 through V4, and EGMs on proxi-
mber of ablation dots might overestimate the actual number of ablation applica-nt Fr
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July 10, 2012:132–41 Endo-Epicardial Homogenization of the Scarassumption for the covariates was tested by Schoenfeld
residual analysis.
Continuous predictors, left ventricular ejection fraction
(LVEF), VT episodes, and VT cycle length, were dichoto-
mized at 30%, 2, and 300, respectively, before enter-
ing into the model. The hazard ratio (HR) and 95%
confidence interval (CI) of VA recurrence were computed.
Recurrence-free survival over time was calculated by the
Kaplan-Meier method, and log-rank statistics was used to
compare the groups. Cohen’s kappa was used to estimate
intercenter agreement in group assignment. All tests were
2-sided, and a p value of 0.05 was considered statistically
significant. Analyses were performed using SAS Version 9.2
(SAS Institute Inc., Cary, North Carolina).
Results
Ninety-two consecutive patients (80% male, 62  13 years,
LVEF 26%  9%) with ischemic cardiomyopathy and ES
undergoing radiofrequency ablation constituted our study
Figure 3 Bipolar Voltage Map of the LV in a Patient From Grou
(A) Endocardial and (B) epicardial maps (inferior views) are shown. Definitions of
(EGMs) of representative endocardial and epicardial mapping site are shown with
grams on proximal (MAP 3-MAP 4) and distal (MAP 1-MAP 2) ablation catheter are
abnormal recordings. Note: the number of ablation dots might overestimate the ac
same radiofrequency application.population. All patients had previously experienced treat- iment failure with 2  0.9 AADs. As described in the
ethods section, patients were divided into 2 groups
ccording to enrollment time. Difference in intercenter distri-
ution of patients in Groups 1 and 2 was assessed using the
appa statistic. No statistically significant bias was noted
kappa  0.57, p  0.01). Among the groups, no significant
ifference in baseline clinical and electrophysiologic character-
stics was observed (Table 1). Importantly, no statistical differ-
nces were observed in terms of VT cycle lengths, percentage
f hemodynamically stable VTs, and scar size (130  54 cm2
vs. 137  66 cm2, p  0.58) (Table 2).
blation data. During the ablation, sustained VT was
nducible in 46 patients (94%) in Group 1 and 42 patients
98%) in Group 2 (p  0.373). Of these, 36 of 46 Group 1
atients (78%) and 34 of 42 Group 2 patients (81%) had
nducible clinical VT. The remaining 10 of 46 Group 1
atients (22%) and 8 of 42 Group 2 patients (19%) had only
onclinical induced VT (Table 2). In Group 1, epicardial
ccess and ablation was performed in 4 patients(8%) due to
r normal myocardium remained the same as in Figures 1 and 2. Electrograms
arrows. In each EGM recording, electrocardiogram leads I, II, and V3 and electro-
. Radiofrequency applications (red dots) were applied at sites demonstrating
umber of ablation applications, because some dots were acquired during thep 2
scar o
white
shown
tual nnducible VTs after endocardial ablation. As previously
1
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Endo-Epicardial Homogenization of the Scar July 10, 2012:132–41mentioned, in these patients, the anticoagulation was re-
versed with protamine, and the epicardial access was ob-
tained in the same ablation session.
In Group 2, epicardial access and mapping were obtained
in all patients, whereas epicardial ablation was performed in
14 cases (33%) due to the presence of delayed, fragmented,
or low voltage potentials on the epicardial surface of the scar
after endocardial ablation. When compared with Group 1,
in Group 2, a higher procedure time (3.6  1.3 h vs. 4.8 
1.5 h, p  0.001), fluoroscopy time (32  14 min vs. 38 
1 min, p  0.017), and radiofrequency time (39  17 vs.
4  21, p  0.001) were reported (Table 2). No statistical
ifference was present between the endocardial maps and
picardial 3-dimensional mapping points (360  15 vs.
70 20 endocardial, and 420 10 vs. 410 6 epicardial)
respectively in Group 1 and in Group 2.
Coronary angiography was performed in 17 patients in
Group 1 (35%) and in 12 patients in Group 2 (28%; p 
0.485).
Acute success of radiofrequency cardiac ablation. At the
end of the procedures, all patients in both groups were free
from inducible or spontaneous VT. The acute procedural
endpoint was achieved in 100% cases. Induction of very fast
VT (cycle length 200 ms) or VF, ventricular flutter, or fast
polymorphic VT after ablation occurred in 9 patients (18%) in
Group 1 and in 5 patients (12%) in Group 2 (p  0.37).
Complications. No periprocedural complication occurred.
One patient in Group 1 and 1 patient in Group 2 died at
follow-up for noncardiac reasons. One hematoma in Group 1 and
1 hematoma in Group 2 not requiring surgery were re-
ported. No post-procedural pericarditis, phrenic nerve palsy,
right ventricle puncture, coronary vessel damages, and
strokes/transient ischemic attacks (peri-procedural and at
Baseline Characteristics andMedical Therapy of the Study PopulationTable 1 B seline Characteristics andMedical Therapy of the Study Population
Group 1 (n  49)
Endocardial
Substrate Ablation
Group 2 (n  43)
Homogenization
of the Scar p Value
Age, yrs 61 10 62 8 0.113
Male 42 (85) 32 (75) 0.173
Hypertension 30 (61) 25 (59) 0.763
Diabetes 8 (16) 6 (13) 0.752
BMI 28 6 28 4 0.279
COPD 4 (8) 3 (6) 1.000
LVEF 27 5 24 8 0.463
History of AF 19 (38) 22 (51) 0.233
Medications
Beta-blocker 45 (92) 36 (84) 0.231
ACEI or ARB 35 (72) 29 (67) 0.678
Sotalol 3 (6) 2 (5) 0.656
Statins 29 (60) 28 (64) 0.558
Clopidogrel 5 (10) 5 (12) 1.000
Values are mean  SD or n (%).
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; ARB  angiotensin
receptor blocker; BMI body mass index; COPD chronic obstructive pulmonary disease; LVEF
eft ventricular ejection fraction.follow-up) were reported.Long-term follow-up. The overall duration of follow-up
for the study population was 25  10 months. However,
compared with patients in Group 2 (median 21 months,
interquartile range 19 to 25 months), who were enrolled at
a later period, patients in Group 1 had a longer follow-up
(median 36 months, interquartile range 27 to 42 months,
p  0.001). In order to exclude the possible confounding
effect of shorter follow-up, assessment of the VT-free
survival was limited to 22 months for both groups. The
probability of recurrence-free survival was significantly
lower in Group 1 (26 [53%] vs. 35 [81%], log-rank p 
0.006). Furthermore, no significant difference in long-term
freedom from arrhythmia recurrence was found among
Group 1 patients who had VT termination during ablation
as compared with those in whom the same endpoint could
not be achieved due to hemodynamic instability during VT
(p  0.67 for comparison).
Kaplan-Meier survival curves are displayed in Figure 4.
The post-procedure AAD use to control recurrent VT
(amiodarone and mexiletine in the majority of patients) was
considerably decreased in Group 2. Of the 35 patients who
were VA free in Group 2, 31 (88%) were off amiodarone
and/or mexiletine compared with 8 (31%) of 26 VA-free
patients off amiodarone and/or mexiletine in Group 1 (p 
0.001). Distribution of VA-free survival was identical across
participating centers; no statistically significant trend in
long-term success was observed (p  0.157).
Of the 8 patients with VT recurrences in Group 2 (6 with
ICD shock, 2 with ATP) at follow-up, 6 (75%, all those
Procedural Parameters and Scar LocationsTable 2 Procedural Parameters and Scar Locations
Group 1 (n  49)
Endocardial
Substrate Ablation
Group 2 (n  43)
Homogenization
of the Scar p Value
Inducible clinical sustained VT 36 (74) 34 (80) 0.245
Nonsustained VT cycle length 340 52 320 40 0.317
Sustained VT cycle length 410 57 430 48 0.476
VT induced 46 (94) 42 (98) 0.793
Number of VTs induced 2 (1–4) 2 (1–5) 0.601
Mappable VT 8 (16) 6 (14) 0.752
Unmappable VT 37 (76) 33 (77) 0.889
Location of scar
Anterior 21 (43) 18 (42) 0.923
Inferior 27 (55) 22 (51) 0.706
Inferoposterior 3 (6) 4 (9) 0.566
Posterior 5 (10) 6 (14) 0.580
Apex 5 (10) 4 (9) 0.885
Septum 4 (8) 3(7) 0.830
Scar size, cm2 130 54 137 66 0.580
Procedure time, h 3.6 1.3 4.8 1.5 0.001
Fluoroscopy time, min 32 14 38 11 0.017
RF time, min 39 17 74 21 0.001
Epicardial access (n) 4 (8) 43 (100) 0.001
Epicardial access and
ablation (n)
4 (8) 14 (33) 0.001Values are mean  SD, median (range), or n (%).
RF  radiofrequency; VT  ventricular tachycardia.
(139JACC Vol. 60, No. 2, 2012 Di Biase et al.
July 10, 2012:132–41 Endo-Epicardial Homogenization of the Scarwith ICD shock) underwent a repeat procedure. Of these
patients, 1 patient had a VT recurrence from outside the
scar area, 1 patient with a large inferior myocardial infarc-
tion required ablation in the right ventricle, 3 patients
underwent epicardial homogenization not performed during
the initial procedure, and only 1 patient required additional
ablation along the endocardial scar that was previously
ablated. Of the 23 patients with VT recurrences of Group 1,
19 (83%) underwent repeat ablation. All these patients were
treated with a scar homogenization approach (5 [26%] with
an endo-epicardial ablation).
Predictors of recurrence. As observed from the univariable
analysis, ablation with homogenization of scar was a deter-
minant of VA-free survival (HR: 0.44; 95% CI: 0.14 to
0.86, p  0.014). No significant association was observed
for other covariates tested in the univariable model; age
(HR: 1.03; 95% CI: 0.92 to 1.07; p  0.473), sex (HR:
1.44; 95% CI: 0.89 to 2.50, p  0.204), LVEF (HR: 0.85;
95% CI: 0.39 to 1.85; p  0.670), VT cycle length (300)
(HR: 1.53; 95% CI: 0.60 to 3.89; p 0.308), scar size (HR:
1.15; 95% CI: 0.74 to 1.79; p 0.527), and amiodarone use
HR: 1.01; 95% CI: 0.99 to 1.03; p  0.487).
Multivariable analysis of recurrence-free survival was per-
formed with the Cox proportional hazards model. Covariates
with clinical importance were entered into the model irrespec-
tive of univariable association. After controlling for important
covariates (age, sex, LVEF, VT cycle length, scar size), ablation
with endo-epicardial homogenization of the scar was found to
be associated with significantly lower risk for VT recurrence
(HR: 0.46; 95% CI: 0.21 to 0.87; p  0.025). Ablation with
endo-epicardial homogenization had 62% decreased risk for
Figure 4 Ventricular Arrhythmia/ICD Therapy-Free
Survival by the Ablation Approach
The Kaplan-Meier curve shows a statistically significant difference between Group 1
(standard ablation approach) and Group 2 (endo-epicardial homogenization
approach) at 25  10 months follow-up. ICD  implantable cardioverter-defibrillator.VT recurrence compared with endocardial ablation alone (Fig. 4).Other baseline risk factors such as sex, age, LVEF, and VT
cycle length did not show any significant influence on
long-term outcome.
A second model was run by adding more covariates
(amiodarone use, VT episodes [2], and VT cycle length)
to the first model. The results from this model were not
different from those of the first one (i.e., homogenization
of scar exhibited significant association with VA-free
survival). On the other hand, including additional pre-
dictors did not add significant prediction power to the
basic model, whereas it incurred the risk of overfitting
and reduced generalizability.
Discussion
Main findings. This is the first study showing that exten-
sive ablation within the scar area in patients with ischemic
heart disease and ES increases the freedom from VAs at
long-term follow-up. Moreover, in the multivariate analysis,
the technique used for the ablation (homogenization of the
scar) was the only predictor of a better outcome. These
results are novel and suggest a new ablation approach for the
treatment of ischemic patients with ES.
None of our patients undergoing ablation had an untreated
reversible trigger favoring the VAs such as acute coronary
ischemia, electrolyte abnormalities, or acute heart failure wors-
ening. Therefore, it appears that in patients with stable
ischemic heart disease and recurrent VAs, a larger area of
tissue needs to be ablated to modify the substrate responsi-
ble for VAs.
General. Ischemic heart disease is the prevalent cardiac
disease in Western countries and, if associated with myo-
cardial infarction and low ejection fraction, exposes patients
to a higher risk of VT and sudden cardiac death. Following
the MADIT 2 (Multicenter Automatic Defibrillator Im-
plantation Trial 2) study, international guidelines have sug-
gested the implantation of ICDs in these patients (1,22).
Despite the presence of the device, the presence of recurrent
VTs and ES represents a marker for increased mortality (23).
AADs are often used but are frequently ineffective and
laden with side effects (24). Catheter ablation of VAs in
patients with ischemic cardiomyopathy and ES have shown
moderate results at long-term follow-up, even after the
introduction of open irrigated ablation (4,5,9,11,15,25).
Although better than medical therapy, the success rate of
the ablation cannot be considered optimal. For these rea-
sons, new technologies and new tools are under investiga-
tion to increase the success rate of catheter ablation (26,27).
Several studies have shown that catheter ablation has a
better success rate at follow-up when compared with AADs
for the treatment of VAs. The success rate ranges from 51%
to 67% and increases in patients with acute efficacy after
ablation (no further mappable VT) (14,28–30).
Specifically for patients with ES, recent studies have also
shown the superiority of catheter ablation to conventional
medical therapy (4), and catheter ablation in this setting
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may offer significant benefit compared with standard med-
ical therapy as a first-line therapy in patients with a single
episode of VT who are undergoing secondary prevention
ICD implantation (31,32).
Most studies have shown that the absence of any VTs at
the inducibility test after ablation was associated with an
increased success rate at follow-up when compared with
series where the acute success was restricted to the nonin-
ducibility of the clinical VT (14,28–30).
Our study confirms these findings. However, noninduc-
ibility of VT(s) was achieved as an endpoint in both groups,
and the different success rate at follow-up may only be
explained by the different ablation strategy. We can specu-
late that the tissue edema created during ablation could
render a reentrant circuit located in deeper layers or in the
surrounding myocardium transiently inactive.
A limited endocardial ablation that does not eliminate all
potential channels and re-entrant circuits might be a potential
cause of ablation failure (33). Of note, a higher number of
patients discontinued AADs in the “homogenization” group,
highlighting the importance of this ablation approach. Inter-
estingly, the endo-epicardial homogenization approach never
required hemodynamic support during the procedure in any of
our patients (vs. 4 [8%] of Group 1 patients), as this approach
eliminates the need for mapping and ablation during tachycar-
dia. These findings, although preliminary, further extend the
benefit of endo-epicardial homogenization, possibly reducing
the risks and the costs of the procedures.
From a pathophysiological perspective, the incremental
effectiveness of endo-epicardial scar homogenization in the
current population of patients with ischemic VT could be
explained by the evolution over the years of post-infarction
arrhythmogenic substrates, which reflects the evolution of
reperfusion therapies for acute myocardial infarction. In the
pre-thrombolytic era, persistent occlusion of the infarct-
related artery generated an area of transmural necrosis,
ultimately leading to a central fibrotic core with a thin
border zone with viable bundles of myocytes interspersed
among healed fibrotic tissue (16). The introduction of
pharmacological and mechanical reperfusion therapies has
led to a higher percentage of nontransmural necrosis, with
heterogeneous infarct cores containing bundles of surviving
myocytes and fibrotic tissue surrounded by similarly com-
plex border zones merging into normal myocardium (16).
Notably, Kumar et al. (34) recently reported a significant
association in humans between the timing of coronary
reperfusion with primary percutaneous coronary interven-
tion and the 2-year rate of spontaneous VAs, with an
incidence ranging from 0% to 14% according to different
timings of coronary reperfusion.
Moreover, the occurrence of the “no-reflow” phenome-
non (17), of distal embolization of thrombotic material
during mechanical reperfusion (18), and varying degrees of
reperfusion-related myocardial injury have further increased
the complexity of the substrate for post-infarction VT,generating multiple slow conduction channels within the
dense scar, with VT exit points located in different areas,
including the subendocardial scar, the border zone, or even
in the mid-wall or subepicardial myocardial layers. As a
result, the presence of multiple slow conduction channels
within the scar and the possibility of mid-wall or epicardial
VT exit sites (19,29) provide the rationale for an extensive
endo-epicardial scar homogenization to treat the current
population of patients with post-infarction VT. Further-
more, a more extensive ablation approach is also justifiable
by recent mechanistic data on the distribution and charac-
teristics of late potentials within the scar (35).
Accordingly, in contrast to what was previously reported
in ischemic VT ablation, a higher number of patients in our
study required epicardial ablation (14).
The results of our study are in line with these concepts
because they show that a more aggressive approach that covers
the entire scar area is associated with a better outcome. In
contrast to what was previously reported in ischemic VT
ablation, a higher number of patients required epicardial
ablation (14). In interpreting our results, one could argue that
the clinical relevance of delayed and fragmented potentials in
the endocardium and in the epicardium is different from what
we have previously believed. As previously mentioned, post-
infarction VTs may also be concealed around the entire scar
area and not limited to a single isthmus. Moreover, the
improved success in Group 2 is likely a result of homogeniza-
tion, as there was not a significant difference between the
outcome of patients undergoing epicardial compared with
those who only had endocardial homogenization.
Study limitations. The major limitation of our study is the
absence of a formal randomization. Although we acknowl-
edge this limitation, the comparison of the ablation strate-
gies has been done in consecutive patients and in a prospec-
tive design. Furthermore, all the procedures have been
performed by highly experienced operators. A minority of
patients in each group had mappable VT, although the
number of mappable VTs was similar to that in previous
studies on ES (4). Furthermore, an endo-epicardial homog-
enization approach is not suitable for patients with previous
coronary artery bypass grafting who, however, represent the
minority of patients with myocardial infarction undergoing
coronary revascularization in the current era (36).
Finally, we cannot exclude that a more dense pace mapping
would have resulted in a better outcome in Group 1 patients.
However, because we empirically targeted a large area around
the presumed VT exit site (Fig. 1), it is unlikely that this might
explain the lower success rate in Group 1.
Conclusions
Our study demonstrates that ablation using endo-epicardial
homogenization of the scar significantly increases freedom
from VAs in patients with ischemic cardiomyopathy and
electrical storm. Further randomized trials are warranted to
confirm the clinical relevance of our study.
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